Stereotactic body radiotherapy (SBRT) is well accepted for low- and intermediate-favorable risk prostate cancer. Available evidence about the application of SBRT in unfavorable- and high-risk prostate cancer is less solid. During last year's multiple variations in treatment, techniques have been reported making comparisons more complicated. This review's objective is to review current evidence in application of SBRT in intermediate unfavourable and high-risk prostate cancer and to outline variations in SBRT treatment techniques and relevant results.
|Number of pages||9|
|Journal||Journal of Radiosurgery and SBRT|
|Publication status||Published - Dec 2022|
Field of Science*
- 3.2 Clinical medicine
- 1.3. Anonymously reviewed scientific article published in a journal with an international editorial board and is available in another indexed database